Company Overview - Oncocyte Corp. is a pioneering diagnostics technology company focused on providing clarity and confidence to physicians and their patients [2] - The company offers several diagnostic tests, including VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™, which are designed for solid organ transplantation monitoring and cancer treatment efficacy [2] Conference Participation - Oncocyte's CEO Josh Riggs and CFO Andrea James will attend BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah on February 11-12, 2025 [1] - The company will host one-on-one meetings with interested investors during the conference [1] Product Information - VitaGraft™ is a clinical blood-based test for solid organ transplantation monitoring [2] - GraftAssure™ is a research use only (RUO) blood-based test for solid organ transplantation monitoring [2] - DetermaIO™ is a gene expression test that evaluates the tumor microenvironment to predict responses to immunotherapies [2] - DetermaCNI™ is a blood-based tool for monitoring therapeutic efficacy in cancer patients [2]

Core Viewpoint - Oncocyte Corp. has announced a registered direct offering and concurrent private placement, aiming to raise $29.1 million to fund its FDA In-Vitro Diagnostic transplant assay program, which is crucial for driving self-sustaining revenue [1][2][4]. Funding Details - The funding round is led by Oncocyte's five largest shareholders, including Bio-Rad Laboratories, with shares priced at $2.05 each [2][7]. - The total gross proceeds from the offerings are expected to be $29.1 million, with 3,609,755 shares sold in the registered direct offering and 7,536,708 shares in the PIPE offering [7][8]. Strategic Partnership - Bio-Rad has committed not only to equity investment but also to providing financial support for upcoming clinical trials and commercialization efforts, highlighting the strength of their strategic partnership [3][10]. Use of Proceeds - The proceeds from the offerings will be utilized for working capital and general corporate purposes, specifically to fund the development of Oncocyte's transplant assay program through FDA clearance [4][5]. Market Potential - Oncocyte aims to capture a share of the $1 billion global transplant testing market, with a focus on improving patient outcomes through innovative diagnostic solutions [6][10]. Technology and Impact - Oncocyte's proprietary technology is designed for transplant centers, offering a simple workflow and rapid results, which can detect kidney transplant rejection signs over 11 months earlier than standard protocols [5][6]. Future Outlook - The company anticipates rapid adoption of its technology post-FDA clearance, with a commitment to financial discipline and capital stewardship as core values moving forward [6][10].

Core Insights - Oncocyte Corp. has appointed Dr. Paul Billings as Consulting Chief Medical Officer to support strategic and clinical goals [2][3] - Dr. Billings is a pioneer in genomics and precision medicine with over 40 years of experience in academia, government, and biotechnology [3][5] - The appointment is expected to enhance Oncocyte's capabilities in regulatory support, reimbursement, business development, and strategic partnerships [6] Company Overview - Oncocyte is a diagnostics technology company focused on providing clarity and confidence to physicians and patients through its tests [7] - Key products include VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™, which are designed for organ transplantation monitoring and cancer treatment efficacy [7][8] - The company aims to improve patient care by enabling testing closer to patients with quality and favorable economics [4]

Core Insights - Oncocyte Corp. has achieved a significant milestone in advancing patient care for kidney transplant patients through the expansion of its VitaGraft Kidney test, which is now confirmed for monitoring patients with newly developed donor-specific antibodies (dnDSA+) for antibody-mediated rejection (AMR) [2][3][11] Group 1: Product Development and Market Expansion - The Molecular Diagnostics program (MolDX) has confirmed the use of VitaGraft Kidney for monitoring dnDSA+ patients, demonstrating its ability to detect AMR up to 11 months earlier than current standards [3][11] - Oncocyte aims to commercialize its proprietary diagnostic technology, which quantifies donor-derived cell-free DNA (dd-cfDNA), allowing local laboratories to run tests more affordably and quickly [5][8] - The expansion of Medicare coverage for VitaGraft Kidney under Local Coverage Determination (LCD) L38568 enhances the total addressable market for the assay, particularly for high-risk patients [6][11] Group 2: Clinical Significance and Impact - Early detection of AMR is critical, as up to 20% of kidney transplant patients may develop detectable DSA within five years, with a significant risk of allograft loss [10] - The test's ability to monitor anti-CD38 therapy is highlighted as a key feature, emphasizing the importance of early detection in the context of emerging therapeutic options [4][10] - The positive coverage decision from Palmetto GBA in August 2023 marks a pivotal step in the commercialization of the assay, confirming its eligibility for Medicare reimbursement [6][10]

IRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay. In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number aberrations (SCNAs) in cerebrospinal fluid. For context, copy number instability (CNI) i ...

Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population Study shows that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies Early detection of transplant rejection is growing in significance as novel therapeutic treatments show promising early results in antibody mediated rejection. Study published in Nephrology Dialysis Transplantation  IRVINE, Calif., Dec. 02, ...

OncoCyte Corporation (NASDAQ:OCX) Q3 2024 Results Conference Call November 12, 2024 5:00 PM ET Company Participants Julie Silber - PCG Advisory Josh Riggs - President and CEO Andrea James - CFO Ekke Schutz - Chief Science Officer Conference Call Participants Joseph Conway - Needham Vidyun Bais - BTIG Operator Thank you for standing by. My name is Kayla, and I will be your conference operator today. At this time, I would like to welcome everyone to the OncoCyte Third Quarter 2024 Earnings Conference Call. Al ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission File Number: 1-37648 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 27-1041563 (State or ...

Exhibit 99.1 Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 ● Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phase ● FDA pre-submission process for approval of kitted clinical test is underway IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX) ("Oncocyte" or the "Company"), a diagnostics tech ...

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ETIRVINE, Calif., Nov. 6, 2024 – PRISM MediaWire –  Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will also host a conference call and webcast on Tuesday, November 12, 2024, at 2:00 ...